Top Page
Aroa Biosurgery Ltd
(Sydney:ARX)
Aroa Biosurgery Ltd (ARX) vs. iShares MSCI Australia ETF (EWA)
Aroa Biosurgery Ltd Business Overview & Revenue Model
Aroa Biosurgery Ltd Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 76.97M | 63.36M | 59.31M | 36.88M | 20.51M |
| Gross Profit | 65.99M | 54.10M | 50.06M | 28.17M | 14.25M |
| EBITDA | 2.65M | -7.36M | 3.50M | -3.75M | -14.56M |
| Net Income | -3.47M | -9.75M | ― | ― | ― |
Balance Sheet | |||||
| Total Assets | 98.94M | 101.88M | 109.07M | 104.71M | 73.12M |
| Cash, Cash Equivalents and Short-Term Investments | 20.13M | 27.73M | 43.00M | 53.35M | 33.93M |
| Total Debt | 5.83M | 6.82M | 6.65M | 5.46M | 14.90M |
| Total Liabilities | 14.35M | 14.79M | 13.69M | 11.30M | 19.43M |
| Stockholders Equity | 84.59M | 87.08M | 95.38M | 93.40M | 53.69M |
Cash Flow | |||||
| Free Cash Flow | -5.69M | -13.31M | ― | ― | ― |
| Operating Cash Flow | -2.33M | -6.84M | ― | -10.86M | -4.68M |
| Investing Cash Flow | 273.54K | 9.31M | 6.79M | ― | ― |
| Financing Cash Flow | -1.34M | -958.48K | ― | 34.98M | 34.06M |
Aroa Biosurgery Ltd Technical Analysis
Aroa Biosurgery Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$203.57M | ― | -4.06% | ― | 20.36% | 64.81% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
| ― | $602.93M | 152.68 | 8.30% | ― | ― | ― | |
| ― | $13.44B | 54.02 | 20.61% | <0.01% | ― | ― | |
49 Neutral | AU$148.37M | ― | -58.61% | ― | ― | -74.88% | |
45 Neutral | AU$120.03M | ― | -35.20% | ― | 4.68% | -155.42% | |
41 Neutral | AU$121.04M | ― | -52.37% | ― | 471.29% | -4.58% |
Aroa Biosurgery Ltd Corporate Events
Aroa Biosurgery Ltd announced a change in the director’s interest, specifically involving Phillip McCaw. The change entails the lapse of 81,925 options due to expiry, impacting McCaw’s indirect holdings through various trusts. This adjustment reflects routine portfolio management and does not indicate any immediate strategic shifts for the company.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced a change in the interests of its director, John Pinion, as per the latest notice to the ASX. The change involved the lapse of 245,775 options exercisable at $0.75 due to expiry, which impacts the director’s holdings but does not alter the number of fully paid ordinary shares held. This update reflects routine adjustments in director holdings, which are part of standard corporate governance practices, and is unlikely to have significant implications for the company’s operations or market position.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced a change in the director’s interest, specifically involving the lapse of options due to expiry. This change reflects a reduction in the number of options held by Director James McLean, which may impact his financial stake in the company but does not affect the overall number of fully paid ordinary shares he holds. Such changes are routine and part of the company’s regulatory compliance, with no immediate implications for stakeholders or the company’s market position.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced a change in the director’s interest, specifically noting the lapse of 3,132,525 options held by Director Brian Ward due to their expiry on July 23, 2025. This change reflects a reduction in Ward’s indirect holdings, which may impact the company’s governance dynamics and stakeholder perceptions, although it does not involve any financial consideration.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced the cessation of 5,104,050 securities due to the expiry of options without exercise or conversion as of July 23, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced it will host a webinar to discuss its June Quarterly Results, which will be released on the same day. This event, featuring CEO Brian Ward and CFO James Agnew, aims to engage investors and interested parties, potentially impacting the company’s market positioning by providing insights into its financial performance and strategic direction.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced the cessation of several securities due to unmet conditions, affecting options and performance share rights. This development may impact the company’s financial strategies and stakeholder interests, as it reflects a reevaluation of certain financial instruments within the organization.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.93 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced a correction to their previously released Appendix 3H regarding the cessation of securities, indicating a misclassification of 245,955 securities that were incorrectly lapsed from ARXAAH instead of ARXAAI. This correction does not affect other cessations included in the original document.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced that its Annual General Meeting will take place on August 20, 2025, where an election of directors will occur. The deadline for director nominations is set for July 2, 2025. This announcement is significant as it outlines the company’s governance timeline and provides stakeholders with the opportunity to influence the company’s leadership, potentially impacting its strategic direction and market positioning.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.93 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced the quotation of 132,979 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code ARX. This move is part of the company’s strategy to enhance its market presence and provide additional liquidity for its stakeholders, potentially strengthening its position in the medical technology industry.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced a change in the director’s interest, specifically regarding Brian Ward’s indirect interest in securities. The change involved the lapse of 591,768 options due to vesting conditions not being met, which impacts the director’s holdings but does not involve any acquisition or disposal of new securities. This update reflects the company’s compliance with ASX listing rules and provides transparency to stakeholders about changes in director interests.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced the cessation of certain securities due to unmet conditions, impacting a total of 2,608,699 securities. This development may affect the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced a change in the director’s interest notice, specifically involving John Diddams. The change includes the transfer of 100,000 fully paid ordinary shares from Galdarn Pty Ltd to Whitfield Investments Pty Ltd, with a total of 160,000 shares disposed of in an on-market sale valued at $77,474.96. This adjustment in shareholding reflects internal financial management and may impact the company’s stock distribution among stakeholders.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced a change in its shareholder registry service provider from Boardroom Pty Ltd to Automic Pty Ltd, effective from June 2, 2025. This transition allows shareholders to manage their holdings more efficiently through Automic’s secure online investor portal, which offers features such as updating shareholder details and viewing transaction history. This change is expected to enhance shareholder engagement and streamline administrative processes, potentially improving the company’s operational efficiency and stakeholder satisfaction.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has released its full-year results for May 2025, highlighting its ongoing commitment to providing regenerative healing solutions. The announcement underscores the company’s strategic focus on advancing its product offerings and maintaining its position in the medical technology industry. This release is significant for stakeholders as it reflects Aroa’s continued growth and potential impact on the healthcare sector, particularly in the areas of wound care and tissue regeneration.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited reported strong financial results for FY25, with a total revenue of NZ$84.7 million, marking a 23% growth from the previous year. The company achieved a positive operating cash flow and a significant improvement in EBITDA, reflecting robust sales of its Myriad and OviTex products. Looking ahead to FY26, Aroa anticipates continued revenue growth driven by Myriad sales and strategic investments in sales productivity and new product development. The company maintains a strong cash position with no debt, positioning it well for future growth.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced an upcoming webinar to discuss its Full Year 2025 Financial Results, which will now be released on May 29, 2025, instead of the previously scheduled May 27. This update reflects the company’s commitment to transparency and engagement with investors and stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced that Australian Ethical Investment Limited has become a substantial holder in the company, with a 5.01% voting power through 17,288,432 ordinary shares. This development signifies a notable investment in Aroa Biosurgery, potentially enhancing its market position and signaling confidence in its growth prospects, which may positively impact stakeholders and the company’s strategic initiatives.
Aroa Biosurgery Ltd released its quarterly report for Q4 FY’25, highlighting its ongoing commitment to advancing regenerative healing technologies. The report, intended for educational purposes, emphasizes the company’s strategic focus on innovation and market expansion. While it does not serve as an investment prospectus, it underscores Aroa’s dedication to enhancing its market position and delivering value to stakeholders through its specialized medical products.
Aroa Biosurgery Limited reported its second consecutive quarter of positive cash flows from operations, with a cash flow of NZ$1.1 million and a strong cash balance of NZ$22.0 million. The company maintained its full-year FY25 revenue guidance, reflecting a 17-22% increase from FY24, and achieved record sales for its Myriad product line in March 2025. Aroa’s strategic initiatives include appointing a US-based Marketing Director to drive market growth and securing unique billing codes for its products to streamline reimbursement processes. The company’s operational progress and financial stability position it well for continued growth and investment in its product lines.